Boris Fehse

14.0k total citations · 2 hit papers
252 papers, 9.2k citations indexed

About

Boris Fehse is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Boris Fehse has authored 252 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 139 papers in Molecular Biology, 84 papers in Genetics and 73 papers in Oncology. Recurrent topics in Boris Fehse's work include Virus-based gene therapy research (81 papers), CRISPR and Genetic Engineering (61 papers) and CAR-T cell therapy research (48 papers). Boris Fehse is often cited by papers focused on Virus-based gene therapy research (81 papers), CRISPR and Genetic Engineering (61 papers) and CAR-T cell therapy research (48 papers). Boris Fehse collaborates with scholars based in Germany, United States and United Kingdom. Boris Fehse's co-authors include Nicolaus Kröger, Axel R. Zander, Christopher Baum, Zhixiong Li, Olga Kustikova, Kristoffer Riecken, Kristoffer Weber, Carol Stocking, Tatjana Zabelina and J. Düllmann and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Boris Fehse

241 papers receiving 9.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Murine Leukemia Induced by Retroviral Gene Marking

2002 515 citations Klaus Kühlcke, Boris Fehse et al. profile →
CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis

2024 78 citations Johanna Richter, Boris Fehse et al. Med profile →

Peers

Countries citing papers authored by Boris Fehse

Since Specialization

Citations

This map shows the geographic impact of Boris Fehse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Boris Fehse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Boris Fehse more than expected).

Fields of papers citing papers by Boris Fehse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Boris Fehse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Boris Fehse. The network helps show where Boris Fehse may publish in the future.

Co-authorship network of co-authors of Boris Fehse

This figure shows the co-authorship network connecting the top 25 collaborators of Boris Fehse. A scholar is included among the top collaborators of Boris Fehse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Boris Fehse. Boris Fehse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A novel approach to refractory idiopathic inflammatory myopathy: CD19 CAR T-cell therapy—case report and literature review 2025 ·Lara D. Veeken ·Isabell Haase, (unknown), (unknown), Boris Fehse, Nikolas Ruffer, (unknown), (unknown), Nico Gagelmann, Dominic Borie, Francis Ayuk, Ina Kötter, Martin Krusche, Nicolaus Kröger	1
2	CD19-Directed CAR T Cell Therapy in 4 Patients with Refractory Multiple Sclerosis 2024 ·Blood ·Johanna Richter, (unknown), (unknown), Boris Fehse, (unknown), Stefanie Reinhardt, (unknown), (unknown), (unknown), Nico Gagelmann, Anita Badbaran, (unknown), (unknown), Christine Wolschke, Dominic Borie, (unknown), Francis Ayuk, Manuel A. Friese, Christoph Heesen, (unknown)	1
3	CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis breakdown → 2024 ·Med ·(unknown), Johanna Richter, (unknown), Boris Fehse, (unknown), Stefanie Reinhardt, Jens Kühle, Anita Badbaran, (unknown), Nico Gagelmann, Dominic Borie, (unknown), Francis Ayuk, Manuel A. Friese, Christoph Heesen, Nicolaus Kröger	78
4	CD45-Directed CAR-T Cells with CD45 Knockout Efficiently Kill Myeloid Leukemia and Lymphoma Cells In Vitro Even after Extended Culture 2024 ·Cancers ·(unknown), (unknown), Dawid Głów, Maximilian Jung, (unknown), Nicolaus Kröger, Stefan Horn, Kristoffer Riecken, Boris Fehse, Francis Ayuk	6
5	Generating Patient-Derived HCC Cell Lines Suitable for Predictive In Vitro and In Vivo Drug Screening by Orthotopic Transplantation 2023 ·Cells ·(unknown), (unknown), Kristoffer Riecken, (unknown), (unknown), Asmus Heumann, (unknown), Manfred Jücker, Boris Fehse, Udo Schumacher, Stefan Lüth, Janine Kah	2
6	Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation 2022 ·Pharmaceutics ·(unknown), Sebastian G. Wicha, Nicolaus Kröger, Alexander J. Muller, (unknown), (unknown), Anita Badbaran, Boris Fehse, Claudia Langebrake	2
7	Influence of Fetomaternal Microchimerism on Maternal NK Cell Reactivity against the Child’s Leukemic Blasts 2022 ·Biomedicines ·(unknown), (unknown), Boris Fehse, Ingo Müller	2
8	Vertically transferred maternal immune cells promote neonatal immunity against early life infections 2021 ·Nature Communications ·Ina A. Stelzer, (unknown), (unknown), Kristin Thiele, Ioanna Triviai, (unknown), Malik Alawi, (unknown), (unknown), Jiabin Huang, Nicole Fischer, Hans‐Willi Mittrücker, María Emilia Solano, Boris Fehse, Anke Diemert, Felix R. Stahl, Petra Arck	50
9	Efficient Pseudotyping of Different Retroviral Vectors Using a Novel, Codon-Optimized Gene for Chimeric GALV Envelope 2021 ·Viruses ·(unknown), (unknown), Boris Fehse, Kristoffer Riecken	7
10	Gene Therapy “Made in Germany”: A Historical Perspective, Analysis of the Status Quo, and Recommendations for Action by the German Society for Gene Therapy 2021 ·Human Gene Therapy ·Hildegard Büning, Boris Fehse, Zoltán Ivics, Stefan Kochanek, Ulrike Koehl, Christian Kupatt, Claudio Mussolino, Dirk M. Nettelbeck, Axel Schambach, Wolfgang Uckert, Ernst Wagner, Toni Cathomen, (unknown)	2
11	Glioma escape signature and clonal development under immune pressure 2020 ·Journal of Clinical Investigation ·Cécile L. Maire, Malte Mohme, Michael Bockmayr, (unknown), Kristoffer Riecken, Daniela Börnigen, Malik Alawi, Antonio Virgilio Failla, Katharina Kolbe, Svenja Zapf, Mareike Holz, Katrin Neumann, Lasse Dührsen, Tobias Lange, Boris Fehse, Manfred Westphal, Katrin Lamszus	28
12	Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs) 2020 ·Cells ·Julia Hambach, Kristoffer Riecken, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Nicolaus Kröger, Timon Hansen, Gunter Schuch, Friedrich Haag, Gerhard Adam, Boris Fehse, Peter Bannas, Friedrich Koch‐Nolte	59
13	Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies 2019 ·Molecular Cancer Therapeutics ·Joseph Tintelnot, (unknown), Christoph Schultheiß, Friederike Braig, (unknown), (unknown), (unknown), Peter Bannas, Boris Fehse, Kristoffer Riecken, (unknown), Carsten Bokemeyer, Thies Rösner, Thomas Valerius, Matthias Peipp, Friedrich Koch‐Nolte, Mascha Binder	26
14	Reversal of P-glycoprotein–Mediated Multidrug Resistance by the Murine Double Minute 2 Antagonist Nutlin-3 2009 ·Cancer Research ·Martin Michaelis, Florian Rothweiler, (unknown), Andreas von Deimling, Kristoffer Weber, Boris Fehse, Bernd Kammerer, Hans Wilhelm Doerr, Jindřich Činátl	83
15	Identification of the Adult Human Hemangioblast 2004 ·Stem Cells and Development ·Sonja Loges, Boris Fehse, Marc A. Brockmann, Katrin Lamszus, (unknown), (unknown), Gunter Schuch, Süleyman Ergün, Uta Fischer, Axel R. Zander, Dieter K. Hossfeld, Walter Fiedler, Ursula M. Gehling	67
16	Influence of Anti-Thymocyte Globulin As Part of the Conditioning Regimen on Immune Reconstitution Following Matched Related Bone Marrow Transplantation 2003 ·Journal of Hematotherapy & Stem Cell Research ·N. Fehse, Boris Fehse, Nicolaus Kröger, Tatjana Zabelina, (unknown), William Krüger, H. Kabisch, R. Erttmann, Axel R. Zander	44
17	Human Mesenchymal Stem Cells Are Not of Donor Origin in Patients with Severe Aplastic Anemia Who Underwent Sex-Mismatched Allogeneic Bone Marrow Transplant 2002 ·Journal of Hematotherapy & Stem Cell Research ·Norbert Stute, Boris Fehse, Jens‐Michael Schröder, (unknown), Peter Adamietz, Karsten R. Held, Axel R. Zander	28
18	Molecular Methods for Detection and Quantification of Myeloma Cells after Bone Marrow Transplantation: Comparison between Real-Time Quantitative and Nested PCR 2002 ·Journal of Hematotherapy & Stem Cell Research ·Florian Tögel, Nicolaus Kröger, Frank Korioth, Boris Fehse, A R Zander	10
19	Real-Time Quantitative Y Chromosome-Specific PCR (QYCS-PCR) for Monitoring Hematopoietic Chimerism after Sex-Mismatched Allogeneic Stem Cell Transplantation 2001 ·Journal of Hematotherapy & Stem Cell Research ·Boris Fehse, (unknown), Klaus Kühlcke, (unknown), (unknown), Helmut Renges, William Krüger, (unknown), (unknown), Friedrich Graf Finckenstein, Nicolaus Kröger, H. Kabisch, Andreas Hochhaus, Axel R. Zander	71
20	Depletion of alloreactive donor T cells using immunomagnetic cell selection 2000 ·Bone Marrow Transplantation ·Boris Fehse, (unknown), (unknown), (unknown), (unknown)	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact